Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.59 |
| ▸ | KYNU | Q16719 | 1/20 | 0.55 |
| ▸ | CTSB | P07858 | 3/20 | 0.54 |
| ▸ | CTSS | P25774 | 3/20 | 0.54 |
| ▸ | CTSL | P07711 | 2/20 | 0.54 |
| ▸ | CTSK | P43235 | 2/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.53 |
| ▸ | TSHR | P16473 | 3/20 | 0.53 |
| ▸ | TACR1 | P25103 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16224709 | 1.00 | ALDH1A1 (0.59) | ALDH1A1ALOX15KYNUCTSBCTSS | |
| SCHEMBL22636059 | 0.93 | TYR (0.56) | ALDH1A1ALOX15CTSBCTSSCTSL | |
| SCHEMBL22636060 | 0.93 | TYR (0.56) | ALDH1A1ALOX15CTSBCTSSCTSL | |
| SCHEMBL22636227 | 0.90 | ITGB3 (0.55) | ALDH1A1ALOX15CTSBCTSSCTSL | |
| SCHEMBL13536730 | 0.90 | ITGB3 (0.55) | ALDH1A1ALOX15CTSBCTSSCTSL | |
| SCHEMBL32677013 | 0.89 | CTSB (0.54) | ALDH1A1CTSBCTSSCTSLCTSK | |
| SCHEMBL19748691 | 0.89 | CTSB (0.54) | ALDH1A1CTSBCTSSCTSLCTSK | |
| SCHEMBL13536741 | 0.88 | ALDH1A1 (0.61) | ALDH1A1ALOX15KYNUCTSBCTSS | |
| SCHEMBL14623159 | 0.88 | ALDH1A1 (0.61) | ALDH1A1ALOX15KYNUCTSBCTSS | |
| SCHEMBL32677070 | 0.88 | CTSB (0.51) | ALDH1A1CTSBCTSSCTSKTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080096942-A1 | Substituted Hydroxyethylamines | ELAN PHARMACEUTICALS, INC. | 2008-04-24 | — | — | US | disclosed |
| US-20080096942-A1 | Substituted Hydroxyethylamines | ELAN PHARMACEUTICALS, INC. | 2008-04-24 | — | — | US | disclosed |
| US-20080096942-A1 | Substituted Hydroxyethylamines | ELAN PHARMACEUTICALS, INC. | 2008-04-24 | — | — | US | disclosed |
| US-7312360-B2 | Substituted hydroxyethylamines | ELAN PHARMACEUTICALS, INC. (US) | 2007-12-25 | — | — | US | disclosed |
| US-7312360-B2 | Substituted hydroxyethylamines | ELAN PHARMACEUTICALS, INC. (US) | 2007-12-25 | — | — | US | disclosed |
| US-7312360-B2 | Substituted hydroxyethylamines | ELAN PHARMACEUTICALS, INC. (US) | 2007-12-25 | — | — | US | disclosed |
| EP-1453788-A1 | SUBSTITUTED HYDROXYETHYLAMINES | Elan Pharmaceuticals, Inc. (US) | 2004-09-08 | — | — | EP | disclosed |
| US-20040044072-A1 | Substituted hydroxyethylamines | PHARMACIA & UPJOHN COMPANY | 2004-03-04 | — | — | US | disclosed |
| WO-2003050073-A1 | SUBSTITUTED HYDROXYETHYLAMINES | ELAN PHARMACEUTICALS, INC. (US) | 2003-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096942-A1 | Substituted Hydroxyethylamines | BACE1, BACE2, MME | ALDH1A1 2044/4885ALOX15 3455/4885KYNU 1631/4885 |
| US-20040044072-A1 | Substituted hydroxyethylamines | BACE1, BACE2, PSEN1 | ALDH1A1 1482/4885ALOX15 3259/4885KYNU 1563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.